. 2012 Jan 10;153(3):1538–1547. doi: 10.1210/en.2011-1864

Table 2.

Thyroid C-cell hyperplasia incidence in wild-type CD-1 and GLP-1R KO mice (n = 36 mice per sex per group) after 13 wk treatment with liraglutide or exenatide

	C-cell hyperplasia (n)
	Liraglutide vehicle, 0 mg/kg · d	Exenatide vehicle, 0 mg/kg · d	Liraglutide			Exenatide, 3 mg/kg · d
	Liraglutide vehicle, 0 mg/kg · d	Exenatide vehicle, 0 mg/kg · d	0.03 mg/kg · d	0.3 mg/kg · d	3 mg/kg · d	Exenatide, 3 mg/kg · d
CD-1 mice
Males	1	0	1	10^a	5	5
Females	0	0	0	8^a	8^a	9^a
GLP-1R KO mice
Males	0	0			0	0
Females	0	0			0	0

P < 0.05 compared to relevant vehicle control.